Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, Japan
Tóm tắt
Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused an international outbreak of coronavirus disease 2019 (COVID-19), data on the clinical characteristics of COVID-19 patients with cancer are limited. This study aimed to evaluate the clinical characteristics and outcomes including mortality and viral shedding period in COVID-19 patients with cancer in Japan. We retrospectively analyzed 32 patients with a history of cancer who were referred to our hospital between January 31, 2020 and May 25, 2020. We evaluated the association between clinical outcomes and potential prognostic factors using univariate analyses. The median age was 74.5 (range 24–90) years and 22 patients (69%) were men. A total of 11 patients (34%) died. Our analyses demonstrated that the mortality was significantly associated with lymphocyte count, albumin, lactate dehydrogenase, serum ferritin, and C-reactive protein on admission. The median period between illness onset and the first effective negative SARS-CoV-2 PCR result was 22 days (interquartile range 18–25) in survivors. Of four patients with hematological malignancy who developed COVID-19 within the rest period of chemotherapy, three died and the other patient, who received bendamustine plus rituximab therapy, had the longest duration of viral shedding (56 days). Our study suggested that the risk factors for mortality previously reported in general COVID-19 patients, including lymphocytopenia, were also effective in cancer patients. Patients who received cytotoxic chemotherapy recently or were treated with chemotherapy, which can lead to lymphocyte reduction, had poor prognosis and prolonged periods of viral shedding.
Tài liệu tham khảo
Zhu N, Zhang D, Wang W et al (2019) A novel coronavirus from patients with pneumonia in China. N Eng J Med 382(8):727–733. https://doi.org/10.1056/NEJMoa2001017
Organization WH (2020) Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 16–24 February 2020
Organization WH (2020) Novel Coronavirus (2019-nCoV): Situation Report-1. 21 January 2020
Liang W, Guan W, Chen R et al (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21(3):335–337. https://doi.org/10.1016/s1470-2045(20)30096-6
Zhang L, Zhu F, Xie L et al (2020) Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol Off J Eur Soc Med Oncol 31(7):894–901. https://doi.org/10.1016/j.annonc.2020.03.296
Zhang H-Y, Wang L-W, Chen Y-Y et al (2020) A multicentre study of 2019 novel coronavirus disease outcomes of cancer patients in Wuhan, China. medRxiv 41:145. https://doi.org/10.1101/2020.03.21.20037127
He W, Chen L, Chen L et al (2020) COVID-19 in persons with haematological cancers. Leukemia 34(6):1637–1645. https://doi.org/10.1038/s41375-020-0836-7
Martín-Moro F, Marquet J, Piris M et al (2020) Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. https://doi.org/10.1111/bjh.16801
Mehta V, Goel S, Kabarriti R et al (2020) Case fatality rate of cancer patients with COVID-19 in a New York Hospital System. Cancer Discov. https://doi.org/10.1158/2159-8290.cd-20-0516
Robilotti EV, Babady NE, Mead PA et al (2020) Determinants of severity in cancer patients with COVID-19 illness. medRxiv. https://doi.org/10.1101/2020.05.04.20086322
Lee LYW, Cazier JB, Starkey T et al (2020) COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet (London, England). https://doi.org/10.1016/s0140-6736(20)31173-9
Kuderer NM, Choueiri TK, Shah DP et al (2020) Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet (London, England). https://doi.org/10.1016/s0140-6736(20)31187-9
Wynants L, Van Calster B, Collins GS et al (2020) Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. BMJ (Clin Res Ed) 369:m1328. https://doi.org/10.1136/bmj.m1328
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244
Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 395(10223):497–506. https://doi.org/10.1016/s0140-6736(20)30183-5
Chen N, Zhou M, Dong X et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) 395(10223):507–513. https://doi.org/10.1016/s0140-6736(20)30211-7
Yang X, Yu Y, Xu J et al (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 8(5):475–481. https://doi.org/10.1016/s2213-2600(20)30079-5
Diao B, Wang C, Tan Y et al (2020) Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol 11:827. https://doi.org/10.3389/fimmu.2020.00827
Jiang M, Guo Y, Luo Q et al (2020) T cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of COVID-19. J Infect Dis. https://doi.org/10.1093/infdis/jiaa252
Liu J, Li S, Liu J et al (2020) Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55:102763. https://doi.org/10.1016/j.ebiom.2020.102763
Wan S, Yi Q, Fan S et al (2020) Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. https://doi.org/10.1101/2020.02.10.20021832
Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England) 395(10229):1054–1062. https://doi.org/10.1016/s0140-6736(20)30566-3
Xiao AT, Tong YX, Gao C et al (2020) Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: a descriptive study. J Clin Virol Off Publ Pan Am Soc Clin Virol 127:104346. https://doi.org/10.1016/j.jcv.2020.104346
Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet (London, England) 381(9873):1203–1210. https://doi.org/10.1016/s0140-6736(12)61763-2
Flinn IW, van der Jagt R, Kahl BS et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123(19):2944–2952. https://doi.org/10.1182/blood-2013-11-531327
Lee LYW, Cazier J-B, Starkey T et al (2020) COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 21(10):1309–1316. https://doi.org/10.1016/S1470-2045(20)30442-3
Mehta P, McAuley DF, Brown M et al (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England) 395(10229):1033–1034. https://doi.org/10.1016/s0140-6736(20)30628-0
Moore JB, June CH (2020) Cytokine release syndrome in severe COVID-19. Science (New York, NY) 368(6490):473–474. https://doi.org/10.1126/science.abb8925
Rotz SJ, Leino D, Szabo S et al. (2017) Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatric Blood Cancer 64(12). https://doi.org/10.1002/pbc.26642
McGonagle D, O’Donnell JS, Sharif K et al (2020) Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. https://doi.org/10.1016/S2665-9913(20)30121-1
Wu C, Chen X, Cai Y et al (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2020.0994
Zhang L, Yan X, Fan Q et al (2020) d-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost JTH 18(6):1324–1329. https://doi.org/10.1111/jth.14859
Walker AJ, Card TR, West J et al (2013) Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer (Oxford, England 1990) 49(6):1404–1413. https://doi.org/10.1016/j.ejca.2012.10.021
Khorana AA, Kuderer NM, Culakova E et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902–4907. https://doi.org/10.1182/blood-2007-10-116327
Guo L, Wei D, Zhang X et al. (2019) Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score. Front Microbiol 10(2752). https://doi.org/10.3389/fmicb.2019.02752